Original Publication Date: 1 January, 2017
Publication / Source: Future Oncology
Authors: Wilson I Gonsalves, Paolo Milani, Daniel Derudas & Francis K Buadi
The advent of various novel therapies such as immunomodulators and proteasome inhibitors has transformed the treatment paradigm for patients with multiple myeloma (MM). As a result, the overall survival has improved dramatically over the last decade. Despite these advances, MM remains mostly incurable and most patients experience disease relapse after enjoying a period of disease control or remission.